Which Are The Toughest Diseases Area To Achieve Clinical Success In?
Executive Summary
In the last decade, on average, only one in 10 Phase I drug development programs conducted in the US have successfully advanced all the way to FDA approval. Meanwhile, despite more than a third of industry's R&D budget being spent on Phase III trials, 42% of programs fail to progress from there, according to a new report from BIO and Informa's Pharma Intelligence.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.